Patents by Inventor Amy Karen Patick

Amy Karen Patick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lentivirus assay system including Vif protein activity
    Publication number: 20050014137
    Abstract: The present invention relates to a lentivirus co-culture assay system that can detect modulation of Vif protein activity and that can be formatted for high throughput screening to identify antiviral agents.
    Type: Application
    Filed: June 29, 2004
    Publication date: January 20, 2005
    Inventors: Wade Stanton Blair, Joan Qun Cao, Amy Karen Patick
  • Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase
    Publication number: 20040235952
    Abstract: The invention relates to methods of inhibiting SARS-related coronavirus viral replication activity comprising contacting a SARS-related coronavirus protease with a therapeutically effective amount of a rhinovirus protease inhibitor, and compositions comprising the same.
    Type: Application
    Filed: April 27, 2004
    Publication date: November 25, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Shella Fuhrman, David A. Matthews, Amy Karen Patick, Paul Rejto
  • Inhibitors of Hepatitis C virus, compositions and treatments using the same
    Publication number: 20040229817
    Abstract: The invention relates to methods of inhibiting HCV viral replication activity comprising contacting an HCV polymerase with a therapeutically effective amount of a hydroxamate MMP inhibitor, and compositions comprising the same.
    Type: Application
    Filed: February 18, 2004
    Publication date: November 18, 2004
    Applicant: AGOURON PHARMACEUTICALS, INC.
    Inventors: Rohit Duggal, Koleen Jill Herlihy, Wei Liu, Amy Karen Patick, Eiann Sha, Weidong Hao
  • Reporter-selectable Hepatitis C virus replicon
    Publication number: 20040214178
    Abstract: The invention relates to a reporter-selectable hepatitis C virus (HCV) replicon, and use of the replicon to generate stable, human hepatoma cell lines. The replicon and cell lines are useful in the compound screening process in HCV drug discovery.
    Type: Application
    Filed: April 24, 2003
    Publication date: October 28, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Rohit Duggal, Amy Karen Patick, Jie Zhang, Weidong Zhao
  • Reporter gene system for use in cell-based assessment of inhibitors of the hepatitis C virus protease
    Patent number: 6790612
    Abstract: A cell-based assay system in which the detection of the reporter gene activity, or secreted alkaline phosphatase (SEAP), is dependent upon the protease activity of the Hepatitis C virus NS3 gene product. This system can be used to assess the activity of candidate protease inhibitors in a mammalian cell-based assay system. The assay system is simpler than previously described assays due to the use of SEAP which allows the reporter gene activity to be quantified by measuring the amount of secreted gene product in the cell media by monitoring the conversion of luminescent or calorimetric alkaline phosphatase substrate.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: September 14, 2004
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Karen Elizabeth Potts, Roberta Lynn Jackson, Amy Karen Patick
  • Reporter gene system for use in cell-based assessment of inhibitors of the hepatitis C virus protease
    Publication number: 20030175692
    Abstract: A cell-based assay system in which the detection of the reporter gene activity, or secreted alkaline phosphatase (SEAP), is dependent upon the protease activity of the Hepatitis C virus NS3 gene product. This system can be used to assess the activity of candidate protease inhibitors in a mammalian cell-based assay system. The assay system is simpler than previously described assays due to the use of SEAP which allows the reporter gene activity to be quantified by measuring the amount of secreted gene product in the cell media by monitoring the conversion of luminescent or calorimetric alkaline phosphatase substrate.
    Type: Application
    Filed: July 10, 2002
    Publication date: September 18, 2003
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Karen Elizabeth Potts, Roberta Lynn Jackson, Amy Karen Patick
  • Reporter gene system for use in cell-based assessment of inhibitors of the hepatitis C virus protease
    Patent number: 6599738
    Abstract: A cell-based assay system in which the detection of the reporter gene activity, or secreted alkaline phosphatase (SEAP), is dependent upon the protease activity of the Hepatitis C virus NS3 gene product. This system can be used to assess the activity of candidate protease inhibitors in a mammalian cell-based assay system. The assay system is simpler than previously described assays due to the use of SEAP which allows the reporter gene activity to be quantified by measuring the amount of secreted gene product in the cell media by monitoring the conversion of luminescent or colorimetric alkaline phosphatase substrate.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: July 29, 2003
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Karen Elizabeth Potts, Roberta Lynn Jackson, Amy Karen Patick
  • Reporter gene system for use in cell-based assessment of inhibitors of the hepatitis C virus protease
    Publication number: 20030082518
    Abstract: A cell-based assay system in which the detection of the reporter gene activity, or secreted alkaline phosphatase (SEAP), is dependent upon the protease activity of the Hepatitis C virus NS3 gene product. This system can be used to assess the activity of candidate protease inhibitors in a mammalian cell-based assay system. The assay system is simpler than previously described assays due to the use of SEAP which allows the reporter gene activity to be quantified by measuring the amount of secreted gene product in the cell media by monitoring the conversion of luminescent or calorimetric alkaline phosphatase substrate.
    Type: Application
    Filed: August 2, 2001
    Publication date: May 1, 2003
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Karen Elizabeth Potts, Roberta Lynn Jackson, Amy Karen Patick
  • Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease
    Patent number: 6280940
    Abstract: A cell-based assay system in which the detection of the reporter gene activity, or secreted alkaline phosphatase (SEAP), is dependent upon the protease activity of the Hepatitis C virus NS3 gene product. This system can be used to assess the activity of candidate protease inhibitors in a mammalian cell-based assay system. The assay system is simpler than previously described assays due to the use of SEAP which allows the reporter gene activity to be quantified by measuring the amount of secreted gene product in the cell media by monitoring the conversion of luminescent or calorimetric alkaline phosphatase substrate.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: August 28, 2001
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Karen Elizabeth Potts, Roberta Lynn Jackson, Amy Karen Patick